Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201

Blood

Volumn 110, Issue 4, 2007, Pages 1105-1111

  Chauvenet, Allen R ^a,b   Martin, Paul L ^c   Devidas, Meenakshi ^b,d   Linda, Stephen B ^b,d   Bell, Beverly A ^e   Kurtzberg, Joanne ^c   Pullen, Jeanette ^f   Pettenati, Mark J ^a   Carroll, Andrew J ^g   Shuster, Jonathan J ^d   Camitta, Bruce ^h  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APHASIA; ARTICLE; ATAXIA; BLOOD TOXICITY; BRAIN HERNIA; BRAIN TOXICITY; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; DRUG EFFECT; HEADACHE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MYELODYSPLASIA; ONCOLOGY; PILOT STUDY; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SEIZURE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 34548014052     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-061689     Document Type: Article

References (57)

1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-2195.
2. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
3. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2001;2:597-607.
4. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
5. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992;79:3316-3324.
6. Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113:103-114.
7. Schrappe M, Reiter A, Zimmerman M, et al. Longterm results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981-1995. Leukemia. 2000;14:2286-2294.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Peto R, Peto J. Asymptotically efficient rank invariant test procedure. J Royal Stat Soc. 1972;135:185-198.
10. National Cancer Institute. Common Toxicity Criteria (CTC). Available at: http://ctep.cancer.gov/forms/CTCv20 4-30-992.pdf. Accessed December 11, 2006.
11. Ganyon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80:1717-1726.
12. Sandlund JT, Harrison PL, Rivera G, et al. Persistence of lymphoblasts on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood. 2002;100:43-47.
13. Wofford MM, Smith SD, Shuster JJ, et al. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1992;10:624-630.
14. Ritchey AK, Pollock BH, Lauer SJ, et al. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol. 1999;17:2745-3752.
15. Chessells JM, Cox TCS, Kendall B, et al. Neurotoxicity in lymphoblastic leukemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child. 1990;65:416-422.
16. Winick NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 1992;84:252-256.
17. Mahoney DH, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphocytic leukemia: an association with intermediate dose methotrexate and intrathecal triple therapy: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712-1722.
18. Rodes S, Bell BA, Abish S, et al. A report of the event-free survival (EFS) and neurotoxicity for children with newly diagnosed standard risk acute lymphoblastic leukemia (ALL) on Pediatric Oncology Group (POG) protocol 9405 [abstract]. Blood. 2005;106:259a. Abstract 882.
19. Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth Disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25:316-320.
20. Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid therapy increases severity of varicella infections in children with lesser risk acute lymphoblastic leukemia. Pediatrics. 2005;116:e525-e529.
21. Aquino VM, Schneider NR, Sandler E. Secondary myelodysplasia with monosomy 7 arising after treatment for acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol. 2001;23:48-50.
22. Carroll WL, Morgan R, Glader BE. Childhood bone marrow monosomy 7 syndrome: a familial disorder? J Pediatr. 1985;107:578-580.
23. Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10 and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children's Oncology Group (COG) initiative. Leukemia. 2005;19:734-740.
24. Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17 and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (-> 50 chromosomes). J Clin Oncol. 2000;18:1876-1887.
25. Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003;102:2756-2762.
26. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990;33:439-450.
27. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.
28. Kamps WA, Bokkerink JPM, Hakvoort-Cammel FGAJ, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial radiation and treatment reduction for standard risk patients: results of DCLSSG protocol ALL-8 (1991-1996). Leukemia. 2002;16:1099-1111.
29. Gustafson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of central nervous system irradiation. Leukemia. 2000;14:2267-2275.
30. Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group trial 1881. J Clin Oncol. 2003;21:1790-1797.
31. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group Overview of 43 randomized trials. J Clin Oncol. 2003;21:1798-1809.
32. Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer. 1998;82:208-218.
33. Pui C-H, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-649.
34. Mattano LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report of the Children's Cancer Group. J Clin Oncol. 2000;18:3262-3272.
35. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314-319.
36. Gilchrist GS, Tubergen DG, Sather HN, et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Children's Cancer Group report. J Clin Oncol. 1994;12:2594-2600.
37. Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
38. Gajjar A, Harrison P, Dandlund J, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96:3381-3384.
39. Pui C-H, Sandland JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
40. Bhatia S, Sather H, Heerema N, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002;100:1957-1964.
41. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Clin Oncol. 2000;18:813-823.
42. Kadan-Lottick NS, Ness K, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2008-2014.
43. Pui C-H, Sunderland JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290:2001-2007.
44. Carroll WL. Race and outcome in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2061-2063.
45. Shuster JJ, Wacker P, Pullen J, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2854-2863.
46. Pui C-H, Boyette JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17:818-824.
47. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
48. Hunger SP, Winick NJ, Sather HN, Carroll WL. Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough? Pediatr Blood Cancer. 2005;45:876-880.
49. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
50. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL 97 randomized trial. Br J Haematol. 2005;129:734-745.
51. Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005;23:6489-6498.
52. Madzo J, Zuna J, Muzikova K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia. Cancer. 2003;97:105-113.
53. Rubnitz JE, Downing JR, Pui C-H, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 1997;15:1150-1157.
54. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
55. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
56. Chauvenet A, Martin P, Bell B, et al. Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group (POG) Study 9201. Ped Blood Cancer. 2005;44:567. Abstract 1717.
57. Chauvenet A, Martin P, Bell B, et al. Anti-metabolite therapy for lesser-risk b-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group (POG) Study 9201: International Society of Pediatric Oncology 2005. Ped Blood Cancer. 2005;45:421. Abstract O148.